Weekly Research Analysts' Ratings Updates for Biogen
They now have a $385.00 price target on the stock, up previously from $321.00. 12/18/2017 - Biogen had its "buy" rating reaffirmed by analysts at Piper Jaffray Companies.
from Biotech News
They now have a $385.00 price target on the stock, up previously from $321.00. 12/18/2017 - Biogen had its "buy" rating reaffirmed by analysts at Piper Jaffray Companies.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments